Verona Pharma (VRNA) to Release Earnings on Monday

Verona Pharma (NASDAQ:VRNA) is scheduled to be issuing its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last released its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same quarter in the previous year, the company earned ($0.11) earnings per share. On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Verona Pharma Stock Up 3.1 %

Shares of VRNA opened at $34.98 on Friday. The company has a quick ratio of 8.61, a current ratio of 8.61 and a debt-to-equity ratio of 0.72. The business has a fifty day moving average of $30.61 and a 200 day moving average of $22.13. The company has a market cap of $2.84 billion, a PE ratio of -22.71 and a beta of 0.42. Verona Pharma has a 52-week low of $11.39 and a 52-week high of $35.62.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VRNA. Canaccord Genuity Group lifted their price target on shares of Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Verona Pharma in a research note on Tuesday, October 1st. Truist Financial upped their target price on Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company assumed coverage on Verona Pharma in a research note on Thursday, October 3rd. They set an “overweight” rating and a $50.00 price target for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verona Pharma presently has a consensus rating of “Buy” and a consensus target price of $39.33.

Insider Buying and Selling at Verona Pharma

In related news, CFO Mark W. Hahn sold 249,728 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.38, for a total value of $1,093,808.64. Following the transaction, the chief financial officer now owns 14,089,960 shares of the company’s stock, valued at $61,714,024.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Mark W. Hahn sold 249,728 shares of Verona Pharma stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.38, for a total value of $1,093,808.64. Following the completion of the sale, the chief financial officer now directly owns 14,089,960 shares in the company, valued at $61,714,024.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David Zaccardelli sold 245,784 shares of the stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92. Following the transaction, the chief executive officer now owns 15,004,920 shares in the company, valued at approximately $65,721,549.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 868,840 shares of company stock valued at $3,805,519 in the last three months. Company insiders own 4.80% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.